Armand Keating, BSc, FRCSC, FRCPC, MD


Two main research areas involve promoting anti- and pro-inflammatory mechanisms to treat arthritis and cancer, respectively:

1) Clinical translation of our newly discovered molecular signature-defined highly potent anti-inflammatory stromal cells in osteoarthritis animal models. This signature of high anti-inflammatory potency consists of a cell surface antigen and two microRNAs present in response to activation of stromal cells by poly(I;C). We are now developing the next generation of cell therapeutics derived from gene-edited iPSC-derived stromal cells rendered safe and non-immunogenic in conjunction with a subsidiary of the Toronto biotechnology company, panCELLa.

2) We have identified a novel therapeutically relevant mechanism of NK killing of cancers—focusing on acute myeloid leukemia—that promotes the pro-inflammatory effects of granule exocytosis driven by the reverse antibody-dependent cell-mediated cytotoxicity {R-ADCC} mechanism. This reverses the usual ADCC mechanism when we employ an antibody to NK natural cytotoxicity receptors in the presence of cancer targets, especially the majority of AML cells that express the Fcγ receptor, CD32. We are currently collaborating with NRC to develop single-domain antibodies against NK-activating receptors, including NKp30, to optimize the R-ADCC.

For a list of Dr. Keating's publications, please visit PubMed or Scopus.

Director, Philip S. Orsino Cell Therapy Translational Research Laboratory, Princess Margaret Hospital
Director, Cell Therapy Program, Princess Margaret Hospital
Professor of Medicine, University of Toronto
Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto
Full Member, Institute of Medical Science, University of Toronto